VIYASH SCIENTIFIC LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1,413 | 1,421 | 1,370 | 1,551 | 3,420 |
| EBITDA (ex other income) | 109 | (53) | 44 | 157 | 608 |
| margin % | 7.7 | (3.7) | 3.2 | 10.1 | 17.8 |
| Owners' profit | 41 | (121) | (36) | 22 | 177 |
| EPS, as reported (₹) | 1.67 | (4.88) | (1.44) | 0.88 | 4.09 |
| ROE % · ROCE % | 6.1 · 7.4 | (16.3) · (10.2) | (4.2) · (0.7) | 4.2 · 9.6 | 7.2 · 11.4 |
| Debt / equity (x) | 0.43 | 0.53 | 0.63 | 0.58 | 0.14 |
| Cash from operations | 31 | 17 | 31 | 83 | 323 |
| Capex | (32) | (86) | (31) | (39) | (135) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 369 | 391 | 402 | 441 | 424 | 858 | 920 | 946 |
| Profit before tax | 8 | 8 | 16 | 26 | 27 | 73 | 125 | 112 |
| Net profit | 6 | 6 | 10 | 18 | 20 | 49 | 66 | 79 |
| EPS (₹) | 0.10 | 0.14 | 0.37 | 0.57 | 0.59 | 0.89 | 1.20 | 1.51 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 8 Sept 2026 · Update on proposed acquisition of BioForLife Italia S.r.l, regulatory approval received | strategic transactions | high | — | — |
| 4 Sept 2026 · Allotment of 612,773 shares under employee stock option plans | capital market events | low | — | — |
| 27 Aug 2026 · Promoters CA Harbor and CA Hull sell over 5 percent stake each in Viyash Scientific | ownership changes | high | — | — |
| 12 Aug 2026 · Viyash Scientific shares Q1 FY27 earnings call audio recording | investor communications | low | — | — |
| 12 Aug 2026 · Newspaper publication of Q1 FY27 financial results | compliance | minimal | — | — |
| 12 Aug 2026 · Q1 FY27 Investor Presentation: Revenue up 19.5%, EBITDA margins expand 530 bps | investor communications | medium | — | — |
| 11 Aug 2026 · AGM voting results: all 6 resolutions passed with strong support | compliance | minimal | — | — |
| 11 Aug 2026 · Viyash Scientific holds 41st AGM, six resolutions passed | board shareholder meetings | medium | — | — |
| 11 Aug 2026 · Q1 FY27 results: Revenue up 19.5%, PAT surges 114.9% | results | medium | — | — |
| 11 Aug 2026 · Q1 profit doubles, 10.3L ESOP shares allotted, Vietnam arm planned | capital market events | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 61.3 | 28.9 | 140 of 169 | 17% |
| P/B | 3.6 | 3.3 | 92 of 163 | 44% |
| ROCE | 9.5 | 10.8 | 103 of 183 | 44% |
| ROE | 7.2 | 10.4 | 111 of 171 | 35% |
| Debt / Equity | 0.1 | 0.1 | 85 of 171 | 51% |
| EBITDA margin | 19.7 | 17.5 | 75 of 165 | 55% |
| Revenue growth | 114.4 | 16.3 | 8 of 161 | 96% |
| Profit growth | 351.3 | 30.9 | 16 of 158 | 90% |
| Market cap | 11227 | 839 | 42 of 182 | 77% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
